Loading...
ROCO
6677
Market cap26mUSD
Jul 09, Last price  
17.50TWD
1D
-2.23%
1Q
-10.49%
IPO
-60.79%
Name

Anxo Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
ROCO:6677 chart
P/E
P/S
1.00
EPS
Div Yield, %
2.28%
Shrs. gr., 5y
2.35%
Rev. gr., 5y
-0.53%
Revenues
843m
-5.81%
877,931,000866,110,000824,100,000866,274,000939,944,000895,320,000843,263,000
Net income
-34m
L-40.34%
24,118,00031,404,00019,234,000-12,558,00021,861,000-57,208,000-34,133,000
CFO
55m
-50.45%
64,476,00059,878,00078,354,00071,269,000-2,655,000111,971,00055,477,000
Dividend
Aug 26, 20240.39898 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Anxo Pharmaceutical Co., Ltd. functions as a specialized enterprise in the pharmaceutical sector. This company is actively involved in the research, production, and global distribution of various medicinal products, catering to both healthcare professionals and individual patients, particularly within Taiwan and across international markets. Its comprehensive product catalog features both prescription-only drugs and over-the-counter remedies, addressing a broad spectrum of therapeutic needs. These include cardiovascular health, metabolic disorders, conditions affecting the central nervous system, diabetes management, respiratory ailments, anti-infective treatments, dermatological issues, nephrology, urology, and orthopedics, among others. More specifically, Anxo supplies agents for antidiabetic and dyslipidemic conditions, supports cardiovascular and circulatory systems, offers therapies for the nervous system, addresses hepatological and gastroenterological concerns, provides anti-infective and antiviral agents, and assists with hemodialysis and urinary system treatments. Additionally, their offerings cover respiratory system and antihistamine applications, various analgesics, and other specialized medications, including a range of injectable pharmaceuticals. Established in 2003, the company's main operational base is situated in Taipei, Taiwan.
IPO date
Jun 27, 2018
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT